APA

Naylor J., Suckow A. T., Seth A., Baker D. J., Sermadiras I., Ravn P., Howes R., Li J., Snaith M. R., Coghlan M. P. & Hornigold D. C. (20170620). Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists. : The Biochemical journal.

Chicago

Naylor Jacqueline, Suckow Arthur T, Seth Asha, Baker David J, Sermadiras Isabelle, Ravn Peter, Howes Rob, Li Jianliang, Snaith Mike R, Coghlan Matthew P and Hornigold David C. 20170620. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists. : The Biochemical journal.

Harvard

Naylor J., Suckow A. T., Seth A., Baker D. J., Sermadiras I., Ravn P., Howes R., Li J., Snaith M. R., Coghlan M. P. and Hornigold D. C. (20170620). Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists. : The Biochemical journal.

MLA

Naylor Jacqueline, Suckow Arthur T, Seth Asha, Baker David J, Sermadiras Isabelle, Ravn Peter, Howes Rob, Li Jianliang, Snaith Mike R, Coghlan Matthew P and Hornigold David C. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists. : The Biochemical journal. 20170620.